Drugs / Cilobradine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02264041 | Jan → Apr 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02264015 | Jan → May 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02264002 | Feb → Nov 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cilobradine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02264002 ↗ |
| Known as | Cilobradina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1436376 ↗ |
| Modality | Small molecule | — CHEMBL1436376 ↗ |
| Route | Oral | “Administered p.o. Once Daily Over 14 Days” NCT02264002 ↗ |